Author: [AUTHOR] Published on 12/1/2023 12:00:00 AM

David Boulton, PhD, Executive Director, AstraZeneca, Gaithersburg, Maryland

What excites you about serving in your role as the Life Cycle Management (LCM) Community Chair?
I work full-time in the LCM space, and I love to bring medicines we understand well to new groups of patients who need them and to improve formulations and devices or routes of administration to make using medicines more convenient for patients. Chairing the LCM Community allows me to gather together like-minded individuals in other pharmaceutical companies and, importantly, regulators, so we can share the science and development strategies to enable getting new medicines to patients safely and efficiently.

What professional accomplishment are you most proud of?
I have worked for 20 years as a clinical pharmacologist on the SGLT2 inhibitor dapagliflozin and still work on it today. I am very proud of being a small part of a very large team that has developed a medicine that has benefited so many people with diabetes (T2DM and T1DM), chronic kidney disease (CKD), and heart failure (HFrEF and HFpEF).

When you are not working, how do you spend your free time?
I mainly drive my two student-athletes around after work and on weekends!

How do you keep focused and motivated?
I think about the patients who will benefit from the new medicines we work on and the truly talented people with whom I get to work.

What is the one thing people would be surprised to know about you?
I am building what will be a road-legal kit car (a Factory Five Racing 818 Coupe) which is taking a long time, but I am able to drive around without a body on it now. I always had something to work on during the pandemic.

David has been a member of ASCPT since 2017.